Rani Therapeutics Holdings annual r&d spending
2020
2021
2022
2023
2024
2025
Rani Therapeutics Holdings R&D Spending Growth & History (RANI)
Rani Therapeutics Holdings's r&d spending was $20.2M for fiscal 2025.
View full Rani Therapeutics Holdings company overviewRani Therapeutics Holdings annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $20.2M | −$6.5M | −24.27% |
| 2024 | 2024-12-31 | $26.7M | −$12.9M | −32.66% |
| 2023 | 2023-12-31 | $39.6M | $3.0M | +8.24% |
| 2022 | 2022-12-31 | $36.6M | $10.1M | +38.23% |
| 2021 | 2021-12-31 | $26.5M | $14.4M | +119.88% |
| 2020 | 2020-12-31 | $12.0M | — | — |
Rani Therapeutics Holdings quarterly r&d spending
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $5.0M | −$488,000 | −8.86% |
| Q1 2026 | 2026-03-31 | $5.2M | −$1.4M | −21.45% |
| Q4 2025 | 2025-12-31 | $4.9M | −$1.9M | −27.90% |
| Q3 2025 | 2025-09-30 | $3.2M | −$3.0M | −47.81% |
| Q2 2025 | 2025-06-30 | $5.5M | −$610,000 | −9.98% |
| Q1 2025 | 2025-03-31 | $6.6M | −$1.0M | −13.39% |
| Q4 2024 | 2024-12-31 | $6.8M | −$797,000 | −10.48% |
| Q3 2024 | 2024-09-30 | $6.2M | −$5.0M | −44.99% |
| Q2 2024 | 2024-06-30 | $6.1M | −$5.0M | −44.84% |
| Q1 2024 | 2024-03-31 | $7.6M | −$2.1M | −21.89% |
| Q4 2023 | 2023-12-31 | $7.6M | −$2.8M | −26.76% |
| Q3 2023 | 2023-09-30 | $11.2M | $2.1M | +23.26% |
| Q2 2023 | 2023-06-30 | $11.1M | $1.6M | +16.35% |
| Q1 2023 | 2023-03-31 | $9.7M | $2.1M | +27.94% |
| Q4 2022 | 2022-12-31 | $10.4M | $3.0M | +40.02% |
| Q3 2022 | 2022-09-30 | $9.1M | −$2.9M | −23.88% |
| Q2 2022 | 2022-06-30 | $9.5M | $5.8M | +153.47% |
| Q1 2022 | 2022-03-31 | $7.6M | $4.2M | +126.80% |
| Q4 2021 | 2021-12-31 | $7.4M | — | — |
| Q3 2021 | 2021-09-30 | $12.0M | $9.9M | +472.20% |
| Q2 2021 | 2021-06-30 | $3.8M | $1.2M | +46.95% |
| Q1 2021 | 2021-03-31 | $3.3M | — | — |
| Q3 2020 | 2020-09-30 | $2.1M | — | — |
| Q2 2020 | 2020-06-30 | $2.6M | — | — |
Rani Therapeutics Holdings r&d spending trends
Over the last five fiscal years, Rani Therapeutics Holdings's r&d spending increased from $12.0M to $20.2M, a change of $8.2M. The latest reported quarter, Q2 2026, shows $5.0M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Rani Therapeutics Holdings source filings ↗